Testosterone is FDA-approved as replacement therapy in men who have low testosterone levels and those with symptoms of hypogonadism. It is essential to distinguish between primary (testicular) and secondary (pituitary-hypothalamic) hypogonadism. This activity reviews the mechanism of action, adverse event profile, and other key factors (e.g., dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent to interprofessional team members exogenous testosterone to treat hypogonadism.

**Objectives:**
- Identify the medically approved indications and contraindications for exogenous androgen replacement therapy.
- Summarize the adverse events and current research on contraindications with androgen replacement therapy.
- Review the dosing parameters for androgen replacement therapy.
- Outline interprofessional team strategies for improving care coordination and communication to advance appropriate clinical outcomes with androgen replacement therapy and improve therapeutic results for the target patient population.